Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 601-606

  Kraeber Bodéré, Françoise ^a,b,e   Salaun, Pierre Yves ^c   Ansquer, Catherine ^a,b   Drui, Delphine ^a   Mirallié, Eric ^a   Faivre Chauvet, Alain ^a,b   Barbet, Jacques ^b   Goldenberg, David M ^d   Chatal, Jean François ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^e HÔTEL DIEU   (France)

Author keywords

Bispecific antibody; Calcitonin; Immuno PET; Medullary thyroid cancer; Pretargeted radioimmunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CALCITONIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; FLUORINE 18; GALLIUM 68; GLUTAMINE DERIVATIVE; HAPTEN; HISTAMINYLSUCCINYLGLUTAMINE; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; PENTETATE INDIUM; UNCLASSIFIED DRUG; YTTRIUM 90; PROTEIN KINASE INHIBITOR;

ARTICLE; BETA RADIATION; BLOOD TOXICITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; OVERALL SURVIVAL; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; RADIATION ABSORPTION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; THERAPEUTIC INDEX; THYROID MEDULLARY CARCINOMA; ANIMAL; METASTASIS; MULTIMODALITY CANCER THERAPY; THYROID TUMOR;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RADIOIMMUNOTHERAPY; THYROID NEOPLASMS;

EID: 84863629950     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0359-6     Document Type: Article

References (47)

1. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995. Cancer. 1998;83:2638-48.
2. Schlumberger M, Carlomagno F, Baudin E, et al. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22-32.
3. Tubiana M, Milhaud G, Coutris G, Lacour J, Parmentier C, Bok B. Medullary carcinoma and thyrocalcitonin. Br Med J. 1968;4:87-9.
4. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-34.
5. Fialkowski E, De Benedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32:754-65.
6. Bergholm U, Bergström R, Ekbom A. Long-term follow-up of patients with medullary thyroid carcinoma of the thyroid. Cancer. 1997;79:132-8.
7. 131I-labeled anti-CEA antibodies. J Nucl Med. 1996;37:905-11.
8. Juweid ME, Hajjar G, Swayne LC, et al. Phase I/II trial of (131) IMN-14F (ab) 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999;85:1828-42.
9. 131I-MN-14F (ab) 2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000;41:93-103.
10. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-34.
11. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol. 1998;48:265-73.
12. Miccoli P, Minuto MN, Ugolini C, et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer. 2007;14:1099-105.
13. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-48.
14. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E. O. R. T. C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-41.
15. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic REToncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-7.
16. Ito Y, Yoshida H, Tomoda C. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett. 2005;229:291-7.
17. Tisell LE, Oden A, Muth A, et al. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89:2093-7.
18. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-84.
19. Mirallié E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-88.
20. Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590-7.
21. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612.
22. Luster M, Karges W, Zeich K, et al. Clinical value of 18-fluorinefluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527-33.
23. 68Ga. J Nucl Med. 2011;52:555-9.
24. 18F radiolabeling for PET. J Nucl Med. 2009;50:991-8.
25. Schoffelen R, Sharkey RM, Goldenberg DM, et al. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga-and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019-27.
26. McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled haptenpeptide. J Nucl Med. 2006;47:1678-88.
27. Hosono M, Hosono M, Kraeber-Bodéré F, et al. Biodistribution and dosimetry study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med. 1998;39:1608-13.
28. Kraeber-Bodéré F, Faivre-Chauvet A, Sai-Maurel C, et al. Comparative toxicity and efficacy of one-and two-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J Nucl Med. 1999;40:198-204.
29. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190-8.
30. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimisation of carcinoembryonic antigen×anti- hapten bispecific antibody mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973-81.
31. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131-I-labeled bivalent hapten in a phase I optimisation clinical trial. J Nucl Med. 2006;47:247-55.
32. Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-11.
33. Salaun PY, Bournaud C, Bardet S, et al. Pretargeted radioimmunotherapy (pRAIT) in progressive metastatic medullary thyroid cancer (MTC): results of a phase II trial. Annual Congress of Society of Nuclear Medicine, San Antonio. 2011.
34. Kraeber-Bodéré F, Saï-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002;1:267-74.
35. Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, et al. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. J Nucl Med. 2010;51:624-31.
36. Salaun PY, Bodet-Milin C, Frampas E, et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer. 2010;116:1053-8.
37. 90Ytrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13:6696-702.
38. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13:535-40.
39. de Groot JWB, Zonnenberg BA, Quarles van Ufford-Mannesse P, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466-9.
40. Frank-Raue K, Fabel M, Delorme S, et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157:215-20.
41. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-801.
42. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323-30.
43. Wells Jr SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-72.
44. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-41.
45. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158-63.
46. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103:6841-6.
47. Schoffelen R, van der Graaf WT, Franssen G, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780-7.